Codexis Enters Agreement With An Unnamed siRNA Drug Innovator To Explore Stereo-Defined Fragment Synthesis Using Its ECO Synthesis Manufacturing Platform

Codexis has entered an agreement with an unnamed siRNA drug innovator to utilize its ECO Synthesis manufacturing platform for producing stereo-defined oligonucleotide fragments. This collaboration follows Codexis's demonstration of full-length siRNA synthesis with precise stereochemical control at TIDES USA 2026. The project aims to compare the performance of enzymatically synthesized fragments against traditional solid-phase oligonucleotide synthesis, potentially enhancing scalability and product quality in future clinical development programs.